Immunomodulatory Agents

DrugDrug NameDrug Indication
DB00060Interferon beta-1aFor treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
DB00068Interferon beta-1bInterferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
DB00108NatalizumabFor treatment of multiple sclerosis.
DB00111DaclizumabZenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
DB01041ThalidomideFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
DB05259GlatiramerFor reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.
DB08880TeriflunomideUsed in the treatment of relapsing forms of multiple sclerosis (MS).
DB11988OcrelizumabIndicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis [FDA Label].
DB05679UstekinumabUstekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease.
DB08868FingolimodFingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
DrugDrug NameTargetType
DB00060Interferon beta-1aInterferon alpha/beta receptor 1target
DB00060Interferon beta-1aInterferon alpha/beta receptor 2target
DB00060Interferon beta-1aCytochrome P450 1A2enzyme
DB00068Interferon beta-1bInterferon alpha/beta receptor 1target
DB00068Interferon beta-1bInterferon alpha/beta receptor 2target
DB00068Interferon beta-1bCytochrome P450 1A2enzyme
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB01041ThalidomideTumor necrosis factortarget
DB01041ThalidomideNuclear factor NF-kappa-B p105 subunittarget
DB01041ThalidomideProstaglandin G/H synthase 2target
DB01041ThalidomideCytochrome P450 2C19enzyme
DB01041ThalidomideCytochrome P450 1A1enzyme
DB01041ThalidomideCytochrome P450 2E1enzyme
DB01041ThalidomideCytochrome P450 2C9enzyme
DB01041ThalidomideProstaglandin G/H synthase 1enzyme
DB01041ThalidomideProstaglandin G/H synthase 2enzyme
DB01041ThalidomideCytochrome P450 3A5enzyme
DB01041ThalidomideFibroblast growth factor receptor 2target
DB01041ThalidomideDNAtarget
DB01041ThalidomideProtein cereblontarget
DB01041ThalidomideNuclear factor kappa-light-chain-enhancer of activated B cellstarget
DB01041Thalidomidealpha1-acid glycoproteintarget
DB05259GlatiramerHLA class II histocompatibility antigen, DRB1-1 beta chaintarget
DB08880TeriflunomideATP-binding cassette sub-family G member 2transporter
DB08880TeriflunomideDihydroorotate dehydrogenase (quinone), mitochondrialtarget
DB08880TeriflunomideCytochrome P450 2C8enzyme
DB08880TeriflunomideSolute carrier organic anion transporter family member 1B1transporter
DB08880TeriflunomideCytochrome P450 1A2enzyme
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB08868FingolimodLeukotriene-B(4) omega-hydroxylase 1enzyme
DB08868FingolimodSphingosine 1-phosphate receptor 5target
DB08868FingolimodSphingosine kinase 1enzyme
DB08868FingolimodCytochrome P450 2E1enzyme
DB08868FingolimodCytochrome P450 4F12enzyme
DB08868FingolimodHistone deacetylase 1target